Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Aspirin use is associated with lower prostate cancer risk in male carriers of BRCA mutations.

Cossack M, Ghaffary C, Watson P, Snyder C, Lynch H.

J Genet Couns. 2014 Apr;23(2):187-91. doi: 10.1007/s10897-013-9629-8. Epub 2013 Jul 25.

PMID:
23881471
2.

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K.

Clin Cancer Res. 2010 Apr 1;16(7):2115-21. doi: 10.1158/1078-0432.CCR-09-2871. Epub 2010 Mar 9.

3.

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA.

Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Erratum in: Eur Urol. 2015 Jun;67(6):e126.

4.

Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME.

BJU Int. 2012 Mar;109(5):713-9. doi: 10.1111/j.1464-410X.2011.10292.x. Epub 2011 Jul 14.

5.
6.

Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.

Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S.

PLoS One. 2009;4(3):e4812. doi: 10.1371/journal.pone.0004812. Epub 2009 Mar 11.

7.

Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.

Mitra AV, Jameson C, Barbachano Y, Sodha N, Kote-Jarai Z, Javed A, Bancroft E, Fletcher A, Cooper C, Peock S; IMPACT and EMBRACE Collaborators, Easton D, Eeles R, Foster CS.

Oncol Rep. 2010 Feb;23(2):299-305.

PMID:
20043088
8.

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.

Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK.

Oncologist. 2015 Jun;20(6):593-7. doi: 10.1634/theoncologist.2014-0425. Epub 2015 May 6.

9.

Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.

Liede A, Metcalfe K, Hanna D, Hoodfar E, Snyder C, Durham C, Lynch HT, Narod SA.

Am J Hum Genet. 2000 Dec;67(6):1494-504. Epub 2000 Nov 3.

10.

Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G.

Ann Oncol. 2011 Apr;22(4):964-6. doi: 10.1093/annonc/mdq460. Epub 2010 Oct 5.

11.

Rapid progression of prostate cancer in men with a BRCA2 mutation.

Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P; Hereditary Breast Cancer Study Group, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C.

Br J Cancer. 2008 Jul 22;99(2):371-4. doi: 10.1038/sj.bjc.6604453. Epub 2008 Jun 24.

12.

Counseling for male BRCA mutation carriers: a review.

Mohamad HB, Apffelstaedt JP.

Breast. 2008 Oct;17(5):441-50. doi: 10.1016/j.breast.2008.05.001. Epub 2008 Jul 26. Review.

PMID:
18657973
13.

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Agalliu I, Gern R, Leanza S, Burk RD.

Clin Cancer Res. 2009 Feb 1;15(3):1112-20. doi: 10.1158/1078-0432.CCR-08-1822.

14.

Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.

Roed Nielsen H, Petersen J, Therkildsen C, Skytte AB, Nilbert M.

Acta Oncol. 2016;55(1):38-44. doi: 10.3109/0284186X.2015.1067714. Epub 2015 Sep 11.

PMID:
26360800
15.

[Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].

Plevová P, Hladíková A.

Klin Onkol. 2012;25 Suppl:S67-73. Czech.

PMID:
22920210
16.

Dietary intake and breast cancer among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study.

Ko KP, Kim SW, Ma SH, Park B, Ahn Y, Lee JW, Lee MH, Kang E, Kim LS, Jung Y, Cho YU, Lee B, Lin JH, Park SK.

Am J Clin Nutr. 2013 Dec;98(6):1493-501. doi: 10.3945/ajcn.112.057760. Epub 2013 Oct 23.

PMID:
24153343
17.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

18.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.

Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.

BMC Cancer. 2008 Apr 10;8:96. doi: 10.1186/1471-2407-8-96.

19.

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.

Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collée MM, Jager A, van Montfort C, Burger CW, Seynaeve C.

Cancer. 2013 Mar 1;119(5):955-62. doi: 10.1002/cncr.27839. Epub 2012 Nov 16.

20.

Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.

Heisey RE, Carroll JC, Warner E, McCready DR, Goel V.

Can Fam Physician. 1999 Jan;45:114-24. Review.

Supplemental Content

Support Center